Fetal exposure to Depakote needs further study, FDA panel says
This article was originally published in Scrip
Executive Summary
At a June 23rd meeting, the US FDA's paediatric advisory committee unanimously concurred, by a vote of 11-0, with a report from agency safety researchers recommending further study of developmental delay reported in children whose mothers took Abbott Laboratories' anti-epileptic Depokote (divalproex sodium).